ArticleOncology letters2019
Development of QSAR machine learning-based models to forecast the effect of substances on malignant melanoma cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development.Drug development research · 2025Review
- Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy.Toxics · 2024Review
- Molecular Toxicity Virtual Screening Applying a Quantized Computational SNN-Based Framework.Molecules (Basel, Switzerland) · 2023Article
- Quantitative Structure-Toxicity Relationship in Bioactive Molecules from a Conceptual DFT Perspective.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Histopathological evaluation of cutaneous malignant melanoma: A retrospective study.Experimental and therapeutic medicine · 2022Article
- Graph-Based Feature Selection Approach for Molecular Activity Prediction.Journal of chemical information and modeling · 2022Article
- QSAR and Molecular Docking Studies of Pyrimidine-Coumarin-Triazole Conjugates as Prospective Anti-Breast Cancer Agents.Molecules (Basel, Switzerland) · 2022Article
- Melanoma in patients with Li-Fraumeni syndrome (Review).Experimental and therapeutic medicine · 2022Review
- Machine Learning Models for Predicting Liver Toxicity.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- In silico prediction of chemical-induced hematotoxicity with machine learning and deep learning methods.Molecular diversity · 2021Article
- Incorporating space and time into random forest models for analyzing geospatial patterns of drug-related crime incidents in a major U.S. metropolitan area.Computers, environment and urban systems · 2021Article
- Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).Experimental and therapeutic medicine · 2021Review
- A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.BMC bioinformatics · 2021Article
- Exposure to cadmium and copper triggers cytotoxic effects and epigenetic changes in human colorectal carcinoma HT-29 cells.Experimental and therapeutic medicine · 2021Article
- In Silico Prediction and Insights Into the Structural Basis of Drug Induced Nephrotoxicity.Frontiers in pharmacology · 2021Article
- Immunohistochemical study of CD117 in various cutaneous melanocytic lesions.Experimental and therapeutic medicine · 2021Article
- An overview of the tumor microenvironment, from cells to complex networks (Review).Experimental and therapeutic medicine · 2021Review
- Multiple primary melanomas: Our experience.Experimental and therapeutic medicine · 2021Article
- Mitochondrial nanotargeting in malignancies (Review).Experimental and therapeutic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SK-MEL-5 is a human melanoma cell line that has been used in various studies to explore new therapies against melanoma in different
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.